EUVIMEDEUVIMED entdecken
Open Access

Actionable Gene Alterations Identified in Patients With Malignant Melanoma by Targeted Sequencing in Japan

Takuro Noguchi iD, Shin Ariga, Rika Moku iD, Junko Kikuchi iD, Toraji Amano iD, Takuya Maeda iD, Kosuke Ishikawa iD, Taku Maeda, Akihiko Shiiya iD, Tomohiro Goda, Yoshihito Ohhara, Kanako Hagio iD und 7 weitere

JCO Precision Oncology · 2025

DOI: 10.1200/po-24-00437 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2025. Verfasst von Takuro Noguchi und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Precision medicine plays an important role in the treatment of patients with advanced melanoma. Despite its high incidence in White patients, advanced melanoma is rare in Asian countries, hampering prospective clinical trials targeting the Asian population. This retrospective study aimed to elucidate the real-world molecular diagnoses and outcomes of Japanese patients with melanoma using comprehensive genome profiling (CGP). MATERIALS AND METHODS Patients with melanoma who completed standard anticancer medical treatments (including those expected to complete the treatments) underwent CGP, which is covered by the National Health Insurance. We analyzed the results and clinical annotations of 569 patients registered before August 2023 in a national database. RESULTS Skin, mucosal, and uveal melanomas accounted for 64%, 28%, and 7% of cases, respectively. Patients with BRAF , NRAS , NF1 , and KIT variants represented 25%, 20%, 17%, and 17%, respectively. Eighty-two percent of BRAF , 97% of NRAS , 69% of NF1 , and 54% of KIT were actionable alterations (ie, BRAF classes I, II, and III, NRAS Q61, G12, G13, NF1 loss-of-function, KIT gain-of-function variants). BRAF V600E/K variants occurred in 22% of skin and 2% of mucosal melanomas, but not in uveal melanomas. The mean tumor mutation burden in cutaneous melanomas was 4.2 variants/Mb. Patients previously treated with BRAF-targeted therapy harbored amplifications of BRAF and cell cycle genes more frequently than therapy-naive patients. Thirty-six patients (6.3%) were treated following the molecular tumor board (MTB) recommendations. CONCLUSION Actionable gene alterations in BRAF , NRAS , NF1 , and KIT are common in Japanese patients with melanoma. However, few patients were treated according to the MTB recommendations, suggesting that there is an unmet need to increase accessibility to gene-matched clinical trials in Japan.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin NeoplasmsHumansMaleFemaleJapanMiddle AgedAgedRetrospective StudiesAdultProto-Oncogene Proteins B-rafProto-Oncogene Proteins c-kitGTP PhosphohydrolasesAged, 80 and overMutationNeurofibromin 1Membrane ProteinsPrecision Medicine

Substanzen

NRAS protein, humanProto-Oncogene Proteins B-rafProto-Oncogene Proteins c-kitGTP PhosphohydrolasesBRAF protein, humanNeurofibromin 1Membrane ProteinsNF1 protein, human

Autor:innen und Institutionen

  • Department of Medical Oncology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan.
  • Department of Medical Oncology, Hokkaido University Hospital, Sapporo, Hokkaido, Japan.
  • Division of Clinical Cancer Genomics, Hokkaido University Hospital, Sapporo, Hokkaido, Japan.
  • Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
  • Department of Plastic and Reconstructive Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
  • Center for Development of Advanced Diagnostics, Hokkaido University Hospital, Sapporo, Japan.

ORCID-Profile: Takuro Noguchi, Rika Moku, Junko Kikuchi, Toraji Amano, Takuya Maeda, Kosuke Ishikawa, Akihiko Shiiya, Kanako Hagio, Kanako C Hatanaka, Yutaka Hatanaka, Satoshi Takeuchi, Ichiro Kinoshita

Zitieren

APA

Noguchi, T., Ariga, S., Moku, R., Kikuchi, J., Amano, T., Maeda, T., Ishikawa, K., Maeda, T., Shiiya, A., Goda, T., Ohhara, Y., Hagio, K., Saito, Y., Hatanaka, K. C., Hatanaka, Y., Taguchi, J., Takeuchi, S., Shimizu, Y., & Kinoshita, I. (2025). Actionable Gene Alterations Identified in Patients With Malignant Melanoma by Targeted Sequencing in Japan. JCO Precision Oncology. https://doi.org/10.1200/po-24-00437

Vancouver

Noguchi T, Ariga S, Moku R, Kikuchi J, Amano T, Maeda T, et al. Actionable Gene Alterations Identified in Patients With Malignant Melanoma by Targeted Sequencing in Japan. JCO Precision Oncology. 2025. doi:10.1200/po-24-00437

BibTeX
@article{Noguchi2025,
  author = {Noguchi, Takuro and Ariga, Shin and Moku, Rika and Kikuchi, Junko and Amano, Toraji and Maeda, Takuya and Ishikawa, Kosuke and Maeda, Taku and Shiiya, Akihiko and Goda, Tomohiro and Ohhara, Yoshihito and Hagio, Kanako and Saito, Yusuke and Hatanaka, Kanako C and Hatanaka, Yutaka and Taguchi, Jun and Takeuchi, Satoshi and Shimizu, Yasushi and Kinoshita, Ichiro},
  title = {Actionable Gene Alterations Identified in Patients With Malignant Melanoma by Targeted Sequencing in Japan},
  journal = {JCO Precision Oncology},
  year = {2025},
  doi = {10.1200/po-24-00437}
}
Kostenlos starten →